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Pretreatment  with  P2Y12 inhibitors  in ST-elevation
myocardial  infarction:  Should  we  keep  doing  it?
Dose  de  carga  de  inibidor  P2Y12  o  mais  cedo  possível  no  contexto  de
enfarte  agudo  do  miocárdio  com  supradesnivelamento  do  segmento  ST:
fazer  ou  não  fazer,  eis  a  questão
Gonçalo Proença























Available online  14  October  2020
Dual  antiplatelet  therapy  is  an  established  and  essential
treatment  in  acute  coronary  syndrome  (ACS)  patients,  with
a  class  I  recommendation  in  the  European  and  American
guidelines.  Current  practice  in  many  centers  still  mandates
an  upfront  loading  dose  with  a  P2Y12 inhibitor  as  soon  as
possible,  before  percutaneous  coronary  intervention  (PCI).
However,  the  evidence  is  scarce  and  conflicting,  and  bene-
fits  from  routine  pretreatment  before  arrival  at  the  cath  lab
remain  uncertain.  This  is  true  for  non-ST-elevation  myocar-
dial  infarction  and  even  more  so  for  ST-elevation  myocardial
infarction  (STEMI)  patients.
What is the rationale of pretreatment?
One  of  the  main  arguments  is  biological  plausibility.1 Since
ACS  most  frequently  results  from  occlusion  of  an  artery  by
a  platelet-rich  thrombus,  it  is  logical  to  assume  that  early
administration  of  aspirin  and  a  P2Y12 inhibitor  should  pro-
vide  greater  benefit,  enabling  the  highest  level  of  platelet
inhibition  in  the  shortest  possible  time.  For  clopidogrel,
still  the  most  frequently  used  P2Y12 inhibitor,  its  pharma-
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uggest  that  pretreatment  with  clopidogrel  in  patients
ith  STEMI  reduces  the  rate  of  ischemic  events  without
xcess  bleeding.2,3 Regarding  ticagrelor,  although  it  does  not
equire  metabolic  activation  to  exert  its  antiplatelet  action,
t  is  still  extensively  metabolized;  its  only  active  metabolite,
R-C124910XX,  is  as  potent  as  ticagrelor  itself.  In  the  setting
f  ACS,  intestinal  uptake  of  ticagrelor  may  be  significantly
elayed,  especially  in  patients  administered  morphine  and
n  those  with  STEMI.4
Besides  these  reasonable  arguments,  a  possible  psycho-
ogical  effect  should  be  borne  in  mind,  arising  from  the
omfort  some  physicians  may  feel  from  doing  something  that
s  thought  of  as  being  biologically  important  for  the  patient,
specially  since  the  same  drug  is  used  in  both  pretreatment
nd  in  cath  lab  loading.  We  live  in  an  era  of  widely  used  and
afer  radial  access,  and  the  number  of  patients  who  require
rgent  bypass  surgery  in  this  context  is  very  small.  Add  the
ell-known  fact  that  times  from  first  medical  contact  to
eperfusion  are  much  longer  than  recommended  in  many
enters  and  the  question  ‘‘why  not  do  it  sooner?’’  begins
o  look  logical.  Unfortunately,  as  in  many  other  clinical  con-
exts,  biological  and  pathophysiological  plausibility  does  not
ecessarily  mean  clinical  efficacy.  When  tested  with  good
ethodology,  plausible  treatments  may  even  prove  harmful.




















































































hat does the most robust evidence available
ell us?
he  Administration  of  Ticagrelor  in  the  Cath  Lab  or  in  the
mbulance  for  New  ST  Elevation  Myocardial  Infarction  to
pen  the  Coronary  Artery  (ATLANTIC)  trial,5 published  in
014,  was  an  international  multicenter  double-blind  trial
hat  recruited  1862  patients  with  STEMI  (<6  hours  duration)
nd  randomized  them  to  ticagrelor  given  prehospital  (in  the
mbulance)  or  in  the  cath  lab.  The  coprimary  endpoints
ere  the  proportion  of  patients  who  did  not  achieve  a 70%
r  greater  resolution  of  ST-segment  elevation  before  PCI  and
he  proportion  of  patients  who  did  not  have  Thrombolysis
n  Myocardial  Infarction  flow  grade  3  in  the  infarct-related
rtery  at  initial  angiography.  Secondary  end  points  included
he  rates  of  major  adverse  cardiovascular  events  and  defi-
ite  stent  thrombosis  at  30  days.  The  take-home  message  of
his  trial  was  that  compared  to  in-hospital  administration,
rehospital  administration  of  ticagrelor  appears  to  be  safe
nd  may  offer  a  small  benefit  in  preventing  stent  throm-
osis  without  any  difference  in  major  bleeding,  but  does
ot  improve  pre-PCI  coronary  reperfusion.  The  time  differ-
nce  between  the  two  arms  was  only  31  minutes,  a small
ifference  that  may  have  played  a  role  in  the  end  result.
More  recently,  using  data  from  the  Swedish  Coronary
ngiography  and  Angioplasty  Registry,6,7 Redfors  et  al.6
tudied  44  804  patients  admitted  with  STEMI  between
005  and  2016,  investigating  the  association  between  pre-
reatment  with  P2Y12 inhibitors  (58.3%  clopidogrel,  35.3%
icagrelor  and  5.3%  prasugrel)  and  the  risk  of  adverse
utcomes  using  a  propensity  score  to  account  for  clus-
ering  of  patients  within  hospitals.  The  primary  endpoint
as  all-cause  mortality  at  30  days.  Secondary  endpoints
ere  infarct-related  artery  occlusion,  30-day  stent  throm-
osis,  in-hospital  bleeding,  neurological  complications  and
ardiogenic  shock.  The  majority  of  patients  (85%)  were
retreated.  The  authors  found  no  statistically  significant
ssociation  between  prehospital  treatment  and  lower  in-
ospital  mortality,  improved  infarct  artery  patency,  lower
tent  thrombosis,  or  higher  bleeding  rates.  However,  confi-
ence  intervals  were  wide,  ranging  from  real  benefit  to
arm,  which  make  firm  conclusions  impossible.
In  this  issue  of  the  Journal,  Guedes  and  coworkers8 return
o  this  open  and  still  unanswered  question.  They  looked  at  a
eries  of  4123  STEMI  patients  admitted  between  2010  and
017  and  compared  those  receiving  a  P2Y12 loading  dose
efore  or  in  the  cath  lab.  The  main  efficacy  endpoint  was
ajor  adverse  events  (MAE)  and  the  main  safety  endpoint
as  a  composite  of  major  bleeding,  hemoglobin  drop  >2
/dl  and  need  for  transfusion.  As  in  the  Swedish  series,  most
atients  received  a  clopidogrel  loading  dose  prior  to  arrival
t  the  cath  lab.  Their  conclusion  is  that  this  strategy  does  not
ppear  to  provide  any  benefit  regarding  mortality  or  MAE.
urthermore,  there  was  an  increased  bleeding  risk,  raising
oncerns  about  safety.8
The  authors  deserve  commendation  for  addressing  this
ssue  and  their  work  provides  yet  another  piece  of  evi-
ence  that  should  be  taken  into  account  by  physicians  when
eciding  the  best  timing  to  administer  a  P2Y12 loading  dose.
owever,  the  limitations  of  this  study  should  be  kept  in  mind:
t  is  retrospective,  the  two  groups  were  very  heterogeneous,
nd  the  time  difference  between  the  groups  in  antiplateletG.  Proença
herapy  administration,  a  critical  piece  of  information,  is
ot  provided.
There  is  thus  still  no  definitive  answer  at  this  time.
nfortunately,  trials  testing  a  strategy  of  very  rapid  onset
nd  high  level  of  P2Y12 receptor  inhibition  at  the  time  of  PCI
sing  intravenous  cangrelor  did  not  address  this  question,
roviding  only  indirect  evidence  suggesting  a  reduction  in
schemic  risk.9
o what should be  done?
s  stated  in  the  current  European  Society  of  Cardiology
TEMI  guidelines,10 earlier  administration  may  be  preferable
o  achieve  early  efficacy,  particularly  when  there  are  long
elays,  which  are  unfortunately  still  very  common.  However,
n  cases  in  which  a  STEMI  diagnosis  is  not  clear,  the  patient
as  a  high  bleeding  risk  or  a  significant  probability  of  under-
oing  surgical  coronary  revascularization  or  whenever  other
tiologies  that  may  require  urgent  surgical  treatment  can-
ot  be  ruled  out,  delaying  P2Y12 inhibitor  loading  must  be
onsidered.
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